Authors

  • Egamova S.K.

Keywords:

chronic lymphocytic leukaemia, interleukin-8, immunological markers, prognosis, immunophenotyping, Binet classification.

References

1. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005;7(2):122–133. doi:10.1215/S115285 1704001061

2. Di Celle PF, Carbone A, Marchis D, et al. Cytokine gene expression in B-cell chronic lymphocytic leukemia: evidence of constitutive interleukin-8 mRNA expression and secretion of biologically active protein. Blood. 1994;84(1):220–228. doi:10.1182/blood.V84.1.220.220

3. Di Celle PF, Mariani S, Riera L, et al. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood. 1996;87(8):4382–4389.

4. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. doi:10.1182/blood-2017-09-806398

5. Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096. doi:10.1038/nrdp.2016.96

6. Maher N, Mouhssine S, Matti BF, Alwan AF, Gaidano G. Treatment refractoriness in chronic lymphocytic leukemia: old and new molecular biomarkers. Int J Mol Sci. 2023;24(12):10374. doi:10.3390/ijms241210374

7. Matsushima K, Oppenheim JJ. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL-1 and TNF. Cytokine. 1989;1(1):2–13. doi:10.1016/1043-4666(89)91043-8

8. Rai KR, Stilgenbauer S. Chronic lymphocytic leukemia: pathogenesis and targeted therapy. Hematology Am Soc Hematol Educ Program. 2021;2021(1):340–348. doi:10.1182/hematology. 2021000264

9. Simbirtsev AS. Interleukin-8 and other chemokines. Immunologiya. 1999;(4):9–14. [In Russian]

10. Smyth MJ, Zachariae CO, Norihisa Y, et al. IL-8 gene expression and production in human peripheral blood lymphocyte subsets. J Immunol. 1991;146(11):3815–3823.

11. Till KJ, Zuzel M, Cawley JS. The role of hyaluronan and interleukin-8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res. 1999;59(17):4419–4436.

12. Vitale C, Boccellato E, Comba L, et al. Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia. Cancers (Basel). 2021;13(15):3856. doi:10.3390/cancers13153856

13. Vodárek P, Écsiová D, Řezáčová V, et al. A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia. Cancer Med. 2023;12(5):5492. doi:10.1002/cam4.5492

14. Wierda WG, Johnson MM, Do KA, et al. Plasma interleukin-8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol. 2003;120(3):452–456. doi:10.1046/j.1365-2141.2003.04077.x

15. Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. 2015;126(4):471–477. doi:10.1182/blood-2015-03-585075